Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
By C. Hans, D. Weisenburger, T. Greiner, R. Gascoyne, J. Delabie, G. Ott, H. Müller-hermelink, E. Campo, R. Braziel, Elaine S. Jaffe and 10 more. Blood, 2004
4,201 citations recorded by the source corpus.
Subfields: Oncology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/a5992d8c142343e6c0e9794c78ae1f8730794a0d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Pathology and Forensic Medicine
Citations in the corpus
- Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. (2012, background): “developed assigning a COO subtype based on the expression of COO-related proteins.(5,6) Unfortunately, the accuracy with which these algorithms correctly classify COO subtype or predict OS is variable among laboratories.”
- Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. (2014, methodology): “Subsequently, in an attempt to determine COO in standard practice using commonly available formalin-fixed paraffin-embedded tissue (FFPET), we and others used less precise(10) but relatively inexpensive binary immunohistochemical (IHC) methods.(11-13) Recently, the feasibility of quantitating gene e”
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms (2022, background): “It is characterized by dependence on BCR signaling and NFκB activities, is negative for most GC markers, and expresses IRF4/ MUM1 [127].”
- MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. (2009, neutral): “More than 80% 7 (58) 27 (22.5) .007 More than 90% 6 (50) 9 (7.5) .001 More than 95% 4 ( 12 ) 8 (6.7) .002”
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas (2017, neutral): “(%) 4/15 (27) 4/21 (19) 4/14 (28) 3/14 (21)”
- Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. (2020, methodology): “Pathologic diagnoses and molecular classification of patients with DLBCL by Hans algorithm were determined locally.(10) Toxicity grading and management were according to each institution’s guidelines.”
- Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012, background): “Cell of origin can also be determined by IHC but published data on the prognostic effect of immunohistochemical techniques are contradictory, and it is not recommended to routinely base clinical decisions on these results [11, 12].”
- BIC and miR‐155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas (2005, methodology): “In DLBCL, BIC expression appears to be associated with an ABC-like phenotype, possibly as a result of NF-κB activation.”